Current R&D
We are currently developing additional products designed to promote tissue repair, reduce inflammation, and deliver soothing, moisturizing benefits. These formulations emphasize safety and affordability, leveraging novel bioactive endogenous molecules.
GI-Tract
Successfully tested in-vitro on IBD models on caco-2 cell lines, for treating inflammatory conditions of the tissue as well as strong anti-permeability effect. We are beginning our first clinical trial on Proctitis.
Following products will be treating esophagitis, colitis, gastritis and Crohn's.
Dermatology
New formulation tested in-vitro for various inflammatory conditions. Tested in two small scale clinical trials for UV exposure and for Atopic Dermatitis. Currently running a third small scale clinical trial testing skin barrier function and erythema.
Ophthalmology
New formulation tested in-vitro on corneal epithelial cell lines for a strong, synergistic anti inflammatory effect. Also tested on a rabbit model for dry eye treatment, extending Tear film Breakup Time, and conjunctival epithelium repair. Human clinical trial to be completed by end of Q3 2025.
Intimate Therapeutics
New anti inflammatory, tissue repair formulations treating GSM related symptoms, dry, irritated and inflamed vaginal tissue, and a formula treating dry, irritated and inflamed conditions of the Vulva and Perineum. Safe, non-hormonal, non-steroidal gel. Clinical trials beginning Q4 2026